GLP-1s for PCOS

Evidence

Small randomized trials of liraglutide and semaglutide in women with PCOS have shown reductions in body weight (4–7%), fasting insulin, free testosterone, and modest improvement in menstrual regularity. Cycle restoration rates of 30–50% have been reported in cohorts with concurrent weight loss.

Clinical use today

Use is off-label and most commonly considered in PCOS patients with concurrent overweight/obesity, insulin resistance, or failed metformin. Contraception is recommended due to teratogenicity risk and the possibility of restored ovulation.

Contraindications

• ✕Active pregnancy or pregnancy planning